Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza – Tender Specifications OJ/2021/DPR/12924  assessing VE among  outpatients or reviews  on relevant VE-related  topics  Manuscripts shall be approved by ECDC prior to submission to a journal.  DL 5.5.4. Draft  summary report to  support the WHO  Vaccine composition  meeting(s) for influenza  on VE among  outpatients Summary reports on interim or final analyses of VE shall be prepared to support  international VE efforts with European data to the WHO Vaccine Composition  meeting twice a year. Two times a year, a  week in advance of  the two Vaccine  composition  meeting’s  Word  DL 5.5.5. Draft  Summary reports on  COVID-19 VE to support  international  assessments such as for  vaccine composition  decisions If and when an international process for COVID-19 vaccine composition decisions  is established, reports supporting this process shall be drafted upon request from  ECDC.  Two times a year  Word  DL 5.5.6.a Prepare and  deliver oral  presentations at  European and  international scientific  conferences (e.g.  ESCAIDE, ESWI, ISIRV,  ERS, ESCMID) Results of VE studies or related methods shall be presented and discussed at  international scientific conferences, such as ESCAIDE, ESWI, ISIRV, ERS, or  ESCMID. Deliverable includes power point preparation and delivery of presentation. Up to five times a  year  PowerPoint  DL 5.5.6.b Travel to  destination for DL  5.5.6.a Travel to destination (accommodation, daily allowance and travel costs) related  to delivery of DL 5.5.6., for an average of 1.5 days of stay  Up to five times a  year 